COVID-19: Hetero seeks permission from DGCI emergency use of Molnupiravir

By Lokmat English Desk | Published: July 9, 2021 03:52 PM2021-07-09T15:52:50+5:302021-07-09T15:55:47+5:30

Hetero has sought permission from the Drug Controller of India for emergency use of the drug Molnupiravir, an effective ...

COVID-19: Hetero seeks permission from DGCI emergency use of Molnupiravir | COVID-19: Hetero seeks permission from DGCI emergency use of Molnupiravir

COVID-19: Hetero seeks permission from DGCI emergency use of Molnupiravir

Next

Hetero has sought permission from the Drug Controller of India for emergency use of the drug Molnupiravir, an effective drug against the coronavirus. Molnupiravir tablet will be a boon for patients with mild symptoms of corona. A medical test conducted by the Hetero company claims that the drug has the ability to eradicate the coronavirus from a patient's body in five days.

In the third phase of interim testing, permission has been sought to test the drug on 1,218 patients. The drug is manufactured by Merck and Ridgeback Biotherapeutics LP. This medicine will be very useful for patients who are not hospitalized and are being treated at home. The final drug test was performed on 714 patients.

The pharmaceutical company Merck had announced agreements with five generic pharmaceutical companies in India for the production of Molnupiravir, a drug similar to the Remedesivir injection, which is effective against the Covid-19 virus. Studies on this drug have shown good results. It was found that the amount of toxins in the body decreases after a patient infected with corona took this drug.

According to the data released by the Union Ministry of Health on Friday , 43,393 new patients have been found in the country in the last 24 hours. 911 people have died. At present, there are 4 lakh 58 thousand 727 active patients in the country.

Open in app